Transporters in the Gastrointestinal Tract

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 221-276

  Anderle, Pascale ^a   Nielsen, Carsten U ^b,c  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ABC; Bioavailability; Colon cancer; Drug delivery; Drug targeting; Gastrointestinal tract; Genomics; Solute carriers; Transporters

Indexed keywords

BIOCHEMISTRY;

BIOAVAILABILITY; COLON CANCER; DRUG-TARGETING; GASTROINTESTINAL TRACT; GENOMICS; SOLUTE CARRIERS; TRANSPORTERS;

DRUG DELIVERY;

EID: 84878022264     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch10     Document Type: Chapter

References (226)

1. Beauchamp, L.M., Orr, G.F., de Miranda, P., Burnette, T. and Krenitsky, T.A. (1992) Amino acid ester prodrugs of acyclovir. Antiviral Chemistry & Chemotherapy, 3, 157-164.
2. de Vrueh, R.L., Smith, P.L. and Lee, C.P. (1998) Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. The Journal of Pharmacology and Experimental Therapeutics, 286 (3), 1166-1170.
3. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L. and Karlsson, J. (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (8), 1333-1340.
4. Kim, H.R., Park, S.W., Cho, H.J., Chae, K. A., Sung, J.M., Kim, J.S., Landowski, C.P., Sun, D., Abd El-Aty, A.M., Amidon, G.L. et al. (2007) Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacological Research, 56 (3), 224-236.
5. Brandsch, M., Knutter, I. and Leibach, F.H. (2004) The intestinal H + /peptide symporter PEPT1: structure-affinity relationships. European Journal of Pharmaceutical Sciences, 21 (1), 53-60.
6. Meredith, D. and Boyd, C.A. (2000) Structure and function of eukaryotic peptide transporters. Cellular and Molecular Life Sciences, 57 (5), 75-778.
7. Nielsen, C.U., Brodin, B., Jorgensen, F.S., Frokjaer, S. and Steffansen, B. (2002) Human peptide transporters: therapeutic applications. Expert Opinion on Therapeutic Patents, 12, 1329-1350.
8. Bretschneider, B., Brandsch, M. and Neubert, R. (1999) Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H + /peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharmaceutical Research, 16 (1), 55-61.
9. Dantzig, A.H. (1998) Oral absorption of beta-lactams by intestinal peptide transport proteins. Advanced Drug Delivery Reviews, 23, 63-76.
10. Han, H., de Vrueh, R.L., Rhie, J.K., Covitz, K.M., Smith, P.L., Lee, C.P., Oh, D.M., Sadee, W. and Amidon, G.L. (1998) 50-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharmaceutical Research, 15 (8), 1154-1159.
11. Landowski, C.P., Han, H.K., Lee, K.D. and Amidon, G.L. (2003) A fluorescent hPept1 transporter substrate for uptake screening. Pharmaceutical Research, 20 (11), 1738-1745.
12. Meredith, D., Temple, C.S., Guha, N., Sword, C.J., Boyd, C.A., Collier, I.D., Morgan, K.M. and Bailey, P.D. (2000) Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. European Journal of Biochemistry, 267 (12), 3723-3728.
13. Dantzig, A.H., Hoskins, J.A., Tabas, L.B., Bright, S., Shepard, R.L., Jenkins, I.L., Duckworth, D.C., Sportsman, J.R., Mackensen, D., Rosteck, P.R., Jr, et al. (1994) Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science, 264 (5157), 430-433.
14. Gao, J., Sudoh, M., Aube, J. and Borchardt, R.T. (2001) Transport characteristics of peptides and peptidomimetics: I. N-methylated peptides as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa. The Journal of Peptide Research, 57 (4), 316-329.
15. Tamai, I. and Safa, A.R. (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. The Journal of Biological Chemistry, 266 (25), 16796-16800.
16. Meier, Y., Eloranta, J.J., Darimont, J., Ismair, M.G., Hiller, C., Fried, M., Kullak-Ublick, G.A. and Vavricka, S.R. (2007) Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (4), 590-594.
17. Ritzel, M.W., Ng, A.M., Yao, S.Y., Graham, K., Loewen, S.K., Smith, K.M., Hyde, R.J., Karpinski, E., Cass, C.E., Baldwin, S.A., et al. (2001) Recent molecular advances in studies of the concentrative Na + -dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Molecular Membrane Biology, 18 (1), 65-72.
18. Ritzel, M.W., Ng, A.M., Yao, S.Y., Graham, K., Loewen, S.K., Smith, K.M., Ritzel, R.G., Mowles, D.A., Carpenter, P., Chen, X.Z. et al. (2001) Molecular identification and characterization of novel human and mouse concentrative Na +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). The Journal of Biological Chemistry, 276 (4), 2914-2927.
19. Huang, Q.Q., Yao, S.Y., Ritzel, M.W., Paterson, A.R., Cass, C.E. and Young, J.D. (1994) Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. The Journal ofBiological Chemistry, 269 (27), 17757-17760.
20. Mackey, J.R., Mani, R.S., Selner, M., Mowles, D., Young, J.D., Belt, J.A., Crawford, C.R. and Cass, C.E. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. CancerResearch, 58 (19), 4349-4357.
21. Mackey, J.R., Yao, S.Y., Smith, K.M., Karpinski, E., Baldwin, S.A., Cass, C.E. and Young, J.D. (1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. Journal of the National Cancer Institute, (21), 1876-1881.
22. Ritzel, M.W., Yao, S.Y., Huang, M.Y., Elliott, J.F., Cass, C.E. and Young, J.D. (1997) Molecular cloning and functional expression of cDNAs encoding a human Na + -nucleoside cotransporter (hCNT1). The American Journal ofPhysiology, 272 (2 Pt 1), C707-C714.
23. Ritzel, M.W., Yao, S.Y., Ng, A.M., Mackey, J. R., Cass, C.E. and Young, J.D. (1998) Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na + /nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Molecular Membrane Biology, 15 (4), 203-211.
24. Broer, S. (2008) Amino acid transport across mammalian intestinal and renal epithelia. Physiological Reviews, 88 (1), 249-286.
25. Chen, Z., Fei, Y.J., Anderson, C.M., Wake, K. A., Miyauchi, S., Huang, W., Thwaites, D.T. and Ganapathy, V. (2003) Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. The Journal of Physiology, 546 (Pt 2), 349-361.
26. Abbot, E.L., Grenade, D.S., Kennedy, D.J., Gatfield, K.M. and Thwaites, D.T. (2006) Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H +-coupled amino-acid transporter hPAT1. British Journal of Pharmacology, 147 (3), 298-306.
27. Thwaites, D.T., Armstrong, G., Hirst, B.H. and Simmons, N.L. (1995) D-cycloserine transport in human intestinal epithelial (Caco-2) cells: mediation by a H( + )-coupled amino acid transporter. British Journal of Pharmacology, 115 (5), 761-766.
28. Wagner, C.A., Lang, F. and Broer, S. (2001) Function and structure of heterodimeric amino acid transporters. American Journal of Physiology - Cell Physiology, 281 (4), C1077-C1093.
29. + as a delivery system for drugs and prodrugs. Current Drug Targets. Immune, Endocrine and Metabolic Disorders, 5 (4), 357-364.
30. Koepsell, H., Lips, K. and Volk, C. (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research, 24 (7), 1227-1251.
31. Koepsell, H. and Endou, H. (2004) The SLC22 drug transporter family. Pflugers Archiv. European Journal of Physiology, 447 (5), 666-676.
32. Ito, K., Suzuki, H., Horie, T. and Sugiyama, Y. (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research, 22 (10), 1559-1577.
33. Halestrap, A.P. and Meredith, D. (2004) The SLC16 gene family - from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv. European Journal of Physiology, 447 (5), 619-628.
34. Englund, G., Rorsman, F., Ronnblom, A., Karlbom, U., Lazorova, L., Grasjo, J., Kindmark, A. and Artursson, P. (2006) Regional levels ofdrug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. European Journal of Pharmaceutical Sciences, 29 (3-4), 269-277.
35. Tamai, I., Takanaga, H., Maeda, H., Sai, Y., Ogihara, T., Higashida, H. and Tsuji, A. (1995) Participation of a protoncotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochemical and Biophysical Research Communications, 214 (2), 482-489.
36. Tsuji, A., Tamai, I., Nakanishi, M., Terasaki, T. and Hamano, S. (1993) Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. The Journal of Pharmacy and Pharmacology, 45 (11), 996-998.
37. Calcagno, A.M., Kim, I.W., Wu, C.P., Shukla, S. and Ambudkar, S.V. (2007) ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Current Drug Delivery, 4 (4), 324-333.
38. Chan, L.M., Lowes, S. and Hirst, B.H. (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences, 21 (1), 25-51.
39. Takano, M., Yumoto, R. and Murakami, T. (2006) Expression and function of efflux drug transporters in the intestine. Pharmacology & Therapeutics, 109 (1-2), 137-161.
40. Loo, T.W., Bartlett, M.C. and Clarke, D.M. (2003) Substrate-induced conformational changes in the transmembrane segments ofhuman P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug, binding. The Journal ofBiological Chemistry, 278 (16), 13603-13606.
41. Loo, T.W. and Clarke, D.M. (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. The Journal of Biological Chemistry, 274 (35), 24759-24765.
42. Benet, L.Z., Izumi, T., Zhang, Y., Silverman, J.A. and Wacher, V.J. (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal ofControlled Release, 62 (1-2), 25-31.
43. Wacher, V.J., Silverman, J.A., Zhang, Y. and Benet, L.Z. (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Journal of Pharmaceutical Sciences, 87 (11), 1322-1330.
44. Wacher, V.J., Wu, C.Y. and Benet, L.Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis, 13 (3), 129-134.
45. Kawahara, M., Sakata, A., Miyashita, T., Tamai, I. and Tsuji, A. (1999) Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Journal ofPharmaceutical Sciences, 88 (12), 1281-1287.
46. Mayer, U., Wagenaar, E., Beijnen, J.H., Smit, J.W., Meijer, D.K., van Asperen, J., Borst, P. and Schinkel, A.H. (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of longterm digoxin accumulation in the brain by the mdr1a P-glycoprotein. British Journal of Pharmacology, 119 (5), 1038-1044.
47. Stephens, R.H., Tanianis-Hughes, J., Higgs, N.B., Humphrey, M. and Warhurst, G. (2002) Region-dependent modulation of intestinal permeability by drug effluxtransporters: in vitro studies in mdr1a(-/-) mouseintestine. The Journal of Pharmacology and Experimental Therapeutics, 303 (3), 1095-1101.
48. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H.K. and Siegmund, W. (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and Therapeutics, 68 (1), 6-12.
49. Balakrishnan, A. and Polli, J.E. (2006) Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Molecular Pharmacology, 3 (3), 223-230.
50. Balakrishnan, A., Wring, S.A. and Polli, J.E. (2006) Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharmaceutical Research, 23 (7), 1451-1459.
51. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., et al. (2001) The sequence of the human genome. Science, 291 (5507), 130-1351.
52. Bates, M.D., Erwin, C.R., Sanford, L.P., Wiginton, D., Bezerra, J.A., Schatzman, L.C., Jegga, A.G., Ley-Ebert, C., Williams, S.S., Steinbrecher, K.A. et al. (2002) Novel genes and functional relationships in the adult mouse gastrointestinal tract identified by microarray analysis. Gastroenterology, 122 (5), 1467-1482.
53. Anderle, P., Sengstag, T., Mutch, D.M., Rumbo, M., Praz, V., Mansourian, R., Delorenzi, M., Williamson, G. and Roberts, M.A. (2005) Changes in the transcriptional profile of transporters in the intestine along the anterior-posterior and crypt-villus axes. BMC Genomics, 6 (1), 69.
54. Mariadason, J.M., Arango, D., Corner, G.A., Aranes, M.J., Hotchkiss, K.A., Yang, W. and Augenlicht, L.H. (2002) A gene expression profile that defines colon cell maturation in vitro. Cancer Research, 62 (16), 4791-4804.
55. Fleet, J.C., Wang, L., Vitek, O., Craig, B.A. and Edenberg, H.J. (2003) Gene expression profiling of Caco-2 BBe cells suggests a role for specific signaling pathways during intestinal differentiation. Physiological Genomics, 13 (1), 57-68.
56. Anderle, P., Rakhmanova, V., Woodford, K., Zerangue, N. and Sadee, W. (2003) MessengerRNAexpressionoftransporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. Pharmaceutical Research, 20 (1), 3-15.
57. Landowski, C.P., Anderle, P., Sun, D., Sadee, W. and Amidon, G.L. (2004) Transporter and ion channel gene expression after Caco-2 cell, differentiation using 2 different microarray technologies. AAPS Journal, 6 (3), e21.
58. Sun, D., Lennernas, H., Welage, L.S., Barnett, J.L., Landowski, C.P., Foster, D., Fleisher, D., Lee, K.D. and Amidon, G.L. (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharmaceutical Research, 19 (10), 1400-1416.
59. Calcagno, A.M., Ludwig, J.A., Fostel, J.M., Gottesman, M.M. and Ambudkar, S.V. (2006) Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Molecular Pharmacology, 3 (1), 87-93.
60. Gentalen, E. and Chee, M. (1999) A novel method for determining linkage between DNA sequences: hybridization to paired probe arrays. Nucleic Acids Research, 27 (6), 1485-1491.
61. Anderle, P., Nielsen, C.U., Pinsonneault, J., Krog, P.L., Brodin, B. and Sadee, W. (2006) Genetic variants of the human dipeptide transporter PEPT1. The Journal of Pharmacology and Experimental Therapeutics, 316 (2), 636-646.
62. Zhang, E.Y., Fu, D.J., Pak, Y.A., Stewart, T., Mukhopadhyay, N., Wrighton, S.A. and Hillgren, K.M. (2004) Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586. The Journal of Pharmacology and Experimental Therapeutics, 310 (2), 437-445.
63. Phan, D.D., Chin-Hong, P., Lin, E.T., Anderle, P., Sadee, W. and Guglielmo, B.J. (2003) Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration ofan hPEPT1 inhibitor. Antimicrobial Agents and Chemotherapy, 47 (7), 2351-2353.
64. Gray, J.H., Mangravite, L.M., Owen, R.P., Urban, T.J., Chan, W., Carlson, E.J., Huang, C.C., Kawamoto, M., Johns, S.J., Stryke, D. et al. (2004) Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Molecular Pharmacology, 65 (3), 512-519.
65. Owen, R.P., Gray, J.H., Taylor, T.R., Carlson, E.J., Huang, C.C., Kawamoto, M., Johns, S.J., Stryke, D., Ferrin, T.E. and Giacomini, K.M. (2005) Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenetics and Genomics, 15 (2), 83-90.
66. Damaraju, S., Zhang, J., Visser, F., Tackaberry, T., Dufour, J., Smith, K.M., Slugoski, M., Ritzel, M.W., Baldwin, S.A., Young, J.D. et al. (2005) Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenetics and Genomics, 15 (3), 173-182.
67. Owen, R.P., Lagpacan, L.L., Taylor, T.R., De LaCruz, M., Huang, C.C., Kawamoto, M., Johns, S.J., Stryke, D., Ferrin, T.E. and Giacomini, K.M. (2006) Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34 (1), 12-15.
68. Kuhne, A., Kaiser, R., Schirmer, M., Heider, U., Muhlke, S., Niere, W., Overbeck, T., Hohloch, K., Trumper, L., Sezer, O. et al. (2007) Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenetics and Genomics, 17 (7), 505-517.
69. Kroetz, D.L., Pauli-Magnus, C., Hodges, L.M., Huang, C.C., Kawamoto, M., Johns, S.J., Stryke, D., Ferrin, T.E., DeYoung, J., Taylor, T. et al. (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics, 13 (8), 481-494.
70. Smith, N.F., Figg, W.D. and Sparreboom, A. (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicology In Vitro, 20 (2), 163-175.
71. Tang, K., Ngoi, S.M., Gwee, P.C., Chua, J.M., Lee, E.J., Chong, S.S. and Lee, C.G. (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics, 12 (6), 437-450.
72. Saito, S., Iida, A., Sekine, A., Miura, Y., Ogawa, C., Kawauchi, S., Higuchi, S. and Nakamura, Y. (2002) Identification of779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). Journal of Human Genetics, 47 (4), 147-171.
73. Leschziner, G., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A.J., Balding, D.J., Bentley, D.B. and Johnson, M.R. (2006) Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenetics and Genomics, 16 (6), 439-450.
74. Andersen, R., Jorgensen, F.S., Olsen, L., Vabeno, J., Thorn, K., Nielsen, C.U. and Steffansen, B. (2006) Development of a QSAR model for binding of tripeptides and tripeptidomimetics to the human intestinal di-/tripeptide transporter hPEPT1. Pharmaceutical Research, 23 (3), 483-492.
75. Bailey, P.D., Boyd, C.A., Bronk, J.R., Collier, I.D., Meredith, D., Morgan, K.M. and Temple, C.S. (2000) How to make drugs orally active: a substrate template for peptide transporter PepT1. Angewandte Chemie, 39 (3), 505-508.
76. Biegel, A., Gebauer, S., Hartrodt, B., Brandsch, M., Neubert, K. and Thondorf, I. (2005) Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H + / peptide cotransporter PEPT1. Journal of Medicinal Chemistry, 48 (13), 4410-4419.
77. Gebauer, S., Knutter, I., Hartrodt, B., Brandsch, M., Neubert, K. and Thondorf, I. (2003) Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H + /peptide cotransporter PEPT1. Journal ofMedicinal Chemistry, 46 (26), 5725-5734.
78. Swaan, P.W., Koops, B.C., Moret, E.E. and Tukker, J.J. (1998) Mapping the binding site ofthe small intestinal peptide carrier (PepT1) using comparative molecular field analysis. Receptors & Channels, 6 (3), 189-200.
79. Swaan, P.W. and Tukker, J.J. (1997) Molecular determinants of recognition for the intestinal peptide carrier. Journal of Pharmaceutical Sciences, 86 (5), 596-602.
80. Vabeno, J., Nielsen, C.U., Steffansen, B., Lejon, T., Sylte, I., Jorgensen, F.S. and Luthman, K. (2005) Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs. Bioorganic and Medicinal Chemistry, 13 (6), 1977-1988.
81. Winiwarter, S. and Hilgendorf, C. (2008) Modeling of drug-transporter interactions using structural information. Current Opinion in Drug Discovery & Development, 11 (1), 95-103.
82. Sugawara, M., Huang, W., Fei, Y.J., Leibach, F.H., Ganapathy, V. and Ganapathy, M.E. (2000) Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. Journal of Pharmaceutical Sciences, 89 (6), 781-789.
83. Jung, D. and Dorr, A. (1999) Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. Journal of Clinical Pharmacology, 39 (8), 800-804.
84. Umapathy, N.S., Ganapathy, V. and Ganapathy, M.E. (2004) Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0, +). Pharmaceutical Research, 21 (7), 1303-1310.
85. Bueno, A.B., Collado, I., de Dios, A., Dominguez, C., Martin, J.A., Martin, L.M., Martinez-Grau, M.A., Montero, C., Pedregal, C., Catlow, J. et al. (2005) Dipeptides as effective prodrugs of the unnatural amino acid (+ )-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. Journal of Medicinal Chemistry, 48 (16), 5305-5320.
86. Landowski, C.P., Song, X., Lorenzi, P.L., Hilfinger, J.M. and Amidon, G.L. (2005) Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharmaceutical Research, 22 (9), 1510-1518.
87. Li, F., Hong, L., Mau, C.I., Chan, R., Hendricks, T., Dvorak, C., Yee, C., Harris, J. and Alfredson, T. (2006) Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. Journal of Pharmaceutical Sciences, 95 (6), 1318-1325.
88. Perkins, E.J. and Abraham, T. (2007) Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2′S)-(2-amino) propionyl]aminobicyclo[3.1.0.]hexen-2,6-di carboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity. Drug Metabolism and Disposition: The Biological Fate ofChemicals, 35 (10), 1903-1909.
89. Song, X., Lorenzi, P.L., Landowski, C.P., Vig, B.S., Hilfinger, J.M. and Amidon, G.L. (2005) Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Molecular Pharmacology, 2 (2), 157-167.
90. Anand, B.S., Patel, J. and Mitra, A.K. (2003) Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. The Journal ofPharmacology and Experimental Therapeutics, 304 (2), 781-791.
91. Jain, R., Duvvuri, S., Kansara, V., Mandava, N.K. and Mitra, A.K. (2007) Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. International Journal of Pharmaceutics, 336 (2), 233-240.
92. Thorn, K., Andersen, R., Christensen, J., Jakobsen, P., Nielsen, C.U., Steffansen, B. and Begtrup, M. (2007) Design, synthesis, and evaluation of tripeptidic promoieties targeting the intestinal peptide transporter hPEPT1. ChemMedChem, 2 (4), 479-487.
93. Chang, C. and Swaan, P.W. (2006) Computational approaches to modeling drug transporters. European Journal of Pharmaceutical Sciences, 27 (5), 411-424.
94. Ekins, S., Johnston, J.S., Bahadduri, P., D'Souza, V.M., Ray, A., Chang, C. and Swaan, P.W. (2005) In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharmaceutical Research, 22 (4), 512-517.
95. + /glucose cotransporter (SGLT1) in the small intestine. Journal ofControlled Release, 125 (1), 42-49.
96. Nozawa, T., Toyobuku, H., Kobayashi, D., Kuruma, K., Tsuji, A. and Tamai, I. (2003) Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. Journal ofPharmaceutical Sciences, 92 (11), 2208-2216.
97. Chen, M.L. (2008) Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Advanced Drug Delivery Reviews, 60 (6), 768-777.
98. Constantinides, P.P. and Wasan, K.M. (2007) Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. Journal of Pharmaceutical Sciences, 96 (2), 235-248.
99. Tamura, K., Bhatnagar, P.K., Takata, J.S., Lee, C.P., Smith, P.L. and Borchardt, R.T. (1996) Metabolism, uptake, and transepithelial transport of the diastereomers ofVal-Val in the human intestinalcell line, Caco-2. Pharmaceutical Research, 13 (8), 1213-1218.
100. Tamura, K., Lee, C.P., Smith, P.L. and Borchardt, R.T. (1996) Metabolism, uptake, and transepithelial transport of the stereoisomers of Val-Val-Val in the human intestinal cell line, Caco-2. Pharmaceutical Research, 13 (11), 1663-1667.
101. Wenzel, U., Thwaites, D.T. and Daniel, H. (1995) Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter. British Journal of Pharmacology, 116 (7), 3021-3027.
102. Nielsen, C.U., Andersen, R., Brodin, B., Frokjaer, S., Taub, M.E. and Steffansen, B. (2001) Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. Journal of Controlled Release, 76 (1-2), 129-138.
103. Taub, M.E., Larsen, B.D., Steffansen, B. and Frokjaer, S. (1997) Beta-carboxylic acid esterified D-Asp-Ala retains a high affinity for the oligopeptide transporter in Caco-2 monolayers. International Journal of Pharmaceutics, 146, 205-212.
104. Taub, M.E., Moss, B.A., Steffansen, B. and Frokjaer, S. (1998) Oligopeptide transporter mediated uptake and transport of D-Asp(OBzl)-Ala, D-Glu (OBzl)-Ala, and D-Ser(Bzl)-Ala in filter-grown Caco-2 monolayers. International Journal of Pharmaceutics, 174, 223-232.
105. Mathews, D.M. and Adibi, S.A. (1976) Peptide absorption. Gastroenterology, 71 (1), 151-161.
106. Doring, F., Walter, J., Will, J., Focking, M., Boll, M., Amasheh, S., Clauss, W. and Daniel, H. (1998) Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. The Journal of Clinical Investigation, 101 (12), 2761-2767.
107. Doring, F., Will, J., Amasheh, S., Clauss, W., Ahlbrecht, H. and Daniel, H. (1998) Minimal molecular determinants of substrates for recognition bythe intestinal peptide transporter. The Journal of Biological Chemistry, 273 (36), 23211-23218.
108. Temple, C.S., Stewart, A.K., Meredith, D., Lister, N.A., Morgan, K.M., Collier, I.D., Vaughan-Jones, R.D., Boyd, C.A., Bailey, P.D. and Bronk, J.R. (1998) Peptide mimics as substrates for the intestinal peptide transporter. The Journal of Biological Chemistry, 273 (1), 20-22.
109. Vabeno, J., Lejon, T., Nielsen, C.U., Steffansen, B., Chen, W., Ouyang, H., Borchardt, R.T. and Luthman, K. (2004) Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations. Journal ofMedicinal Chemistry, 47 (4), 1060-1069.
110. Vabeno, J., Nielsen, C.U., Ingebrigtsen, T., Lejon, T., Steffansen, B. and Luthman, K. (2004) Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations. Journal of Medicinal Chemistry, 47 (19), 4755-4765.
111. Brandsch, M., Thunecke, F., Kullertz, G., Schutkowski, M., Fischer, G. and Neubert, K. (1998) Evidence for the absolute conformational specificity ofthe intestinal H + /peptide symporter, PEPT1. TheJournalofBiological Chemistry, 273 (7), 3861-3864.
112. Brandsch, M., Knutter, I., Thunecke, F., Hartrodt, B., Born, I., Borner, V., Hirche, F., Fischer, G. and Neubert, K. (1999) Decisive structural determinants for the interaction of proline derivatives with the intestinal H + /peptide symporter. European Journal of Biochemistry, 266 (2), 502-508.
113. Addison, J.M., Burston, D. and Matthews, D.M. (1972) Evidence for active transport of the dipeptide glycylsarcosine by hamster jejunum in vitro. Clinical Science, 43 (6), 907-911.
114. Andersen, R., Nielsen, C.U., Begtrup, M., Jorgensen, F.S., Brodin, B., Frokjaer, S. and Steffansen, B. (2006) In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1. European Journal of Pharmaceutical Sciences, 28 (4), 325-335.
115. Nielsen, C.U., Supuran, C.T., Scozzafava, A. , Frokjaer, S., Steffansen, B. and Brodin, B. (2002) Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line. Pharmaceutical Research, 19 (9), 1337-1344.
116. Borner, V., Fei, Y.J., Hartrodt, B., Ganapathy, V., Leibach, F.H., Neubert, K. and Brandsch, M. (1998) Transport of amino acid aryl amides by the intestinal H + /peptide cotransport system, PEPT1. European Journal of Biochemistry, 255 (3), 698-702.
117. Cheng, Y. and Prusoff, W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology, 22 (23), 3099-3108.
118. Merlin, D., Steel, A., Gewirtz, A.T., Si-Tahar, M., Hediger, M.A. and Madara, J.L. (1998) hPepT1-mediated epithelial transport of bacteria-derived chemotactic peptides enhances neutrophil-epithelial interactions. The Journal of Clinical Investigation, 102 (11), 2011-2018.
119. Ganapathy, M.E., Prasad, P.D., Mackenzie, B., Ganapathy, V. and Leibach, F.H. (1997) Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochimica et Biophysica Acta, 1324 (2), 296-308.
120. Doring, F., Theis, S. and Daniel, H. (1997) Expression and functional characterization of the mammalian intestinal peptide transporter PepT1 in the methylotropic yeast Pichia pastoris. Biochemical and Biophysical Research Communications, 232 (3), 656-662.
121. Amasheh, S., Wenzel, U., Boll, M., Dorn, D., Weber, W., Clauss, W. and Daniel, H. (1997) Transport of charged dipeptides by the intestinal H + /peptide symporter PepT1 expressed in Xenopus laevis oocytes. The Journal of Membrane Biology, 155 (3), 247-256.
122. Knutter, I., Hartrodt, B., Theis, S., Foltz, M., Rastetter, M., Daniel, H., Neubert, K. and Brandsch, M. (2004) Analysis of the transport properties of side chain modified dipeptides at the mammalian peptide transporter PEPT1. European Journal of Pharmaceutical Sciences, 21 (1), 61-67.
123. Kottra, G. and Daniel, H. (2001) Bidirectional electrogenic transport of peptides by the proton-coupled carrier PEPT1 in Xenopus laevis oocytes: its asymmetry and symmetry. The Journal of Physiology, 536 (Pt 2), 495-503.
124. Faria, T.N., Timoszyk, J.K., Stouch, T.R., Vig, B.S., Landowski, C.P., Amidon, G.L., Weaver, C.D., Wall, D.A. and Smith, R.L. (2004) A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. Molecular Pharmacology, 1 (1), 67-76.
125. Herrera-Ruiz, D., Faria, T.N., Bhardwaj, R.K., Timoszyk, J., Gudmundsson, O.S., Moench, P., Wall, D.A., Smith, R.L. and Knipp, G.T. (2004) A novel hPepT1 stably transfected cell line: establishing a correlation between expression and function. Molecular Pharmacology, 1 (2), 136-144.
126. Vig, B.S., Stouch, T.R., Timoszyk, J.K., Quan, Y., Wall, D.A., Smith, R.L. and Faria, T.N. (2006) Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. Journal of Medicinal Chemistry, 49 (12), 3636-3644.
127. Balimane, P.V., Chong, S., Patel, K., Quan, Y., Timoszyk, J., Han, Y.H., Wang, B., Vig, B. and Faria, T.N. (2007) Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Archives ofPharmacal Research, 30 (4), 507-518.
128. Smith, P.L. (1996) Methods for evaluating intestinal permeability and metabolism in vitro. Pharmaceutical Biotechnology, 8, 13-34.
129. Larsen, S.B., Jorgensen, F.S. and Olsen, L. (2008) QSAR models for the human H (+ )/peptide symporter, hPEPT1: affinity prediction using alignment-independent descriptors. Journal of Chemical InformationandModeling, 48 (1), 233-241.
130. Swaan, P.W., Stehouwer, M.C. and Tukker, J.J. (1995) Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochimica et Biophysica Acta, 1236 (1), 31-38.
131. Zhu, Z. and Buolamwini, J.K. (2008) Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorganic and Medicinal Chemistry, 16 (7), 3848-3865.
132. Kharkar, P.S., Reith, M.E. and Dutta, A.K. (2008) Three-dimensional quantitative structure-activityrelationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors. Journal ofComputer-Aided Molecular Design, 22 (1), 1-17.
133. Chang, C., Swaan, P.W., Ngo, L.Y., Lom, P.Y., Patil, S.D., Unadkat, J.D. (2004) Molecular requirements ofthe nucleotide transportershCNT1,hCNT2, andhENT1. Molecular Pharmacology, 65, 558-570.
134. Ekins, S., Ecker, G.F., Chiba, P. and Swaan, P.W. (2007) Future directions for drug transporter modelling. Xenobiotica; The Fate ofForeign Compounds in Biological Systems, 37 (10-11), 1152-1170.
135. Petrovic, V., Teng, S. and Piquette-Miller, M. (2007) Regulation ofdrug transporters during infection and inflammation. Molecular Interventions, 7 (2), 99-111.
136. Edinger, A.L. (2007) Controlling cell growth and survival through regulated nutrient, transporter expression. The Biochemical Journal, 406 (1), 1-12.
137. Surh, Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nature Reviews. Cancer, 3 (10), 768-780.
138. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100 (1), 57-70.
139. Coussens, L.M. and Werb, Z. (2002) Inflammation and cancer. Nature, 420 (6917), 860-867.
140. Thiery, J.P. and Sleeman, J.P. (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews. Molecular Cell Biology, 7 (2), 131-142.
141. Bhowmick, N.A. and Moses, H.L. (2005) Tumor-stroma interactions. Current Opinion in Genetics & Development, 15 (1), 97-101.
142. Bhowmick, N.A., Neilson, E.G. and Moses, H.L. (2004) Stromal fibroblasts in cancer initiation and progression. Nature, 432 (7015), 332-337.
143. De Wever, O. and Mareel, M. (2003) Role of tissue stroma in cancer cell invasion. The Journal of Pathology, 200 (4), 429-447.
144. Liotta, L.A. and Kohn, E.C. (2001) The microenvironment of the tumour-host interface. Nature, 411 (6835), 375-379.
145. Tlsty, T.D. and Hein, P.W. (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. Current Opinion in Genetics & Development, 11 (1), 54-59.
146. Elenbaas, B. and Weinberg, R.A. (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Experimental Cell Research, 264 (1), 169-184.
147. Sugiyama, Y., Farrow, B., Murillo, C., Li, J., Watanabe, H., Sugiyama, K. and Evers, B.M. (2005) Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology, 128 (2), 480-486.
148. Mueller, M.M. and Fusenig, N.E. (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nature Reviews. Cancer, 4 (11), 839-849.
149. Micke, P. and Ostman, A. (2004) Tumour-stroma interaction: cancer-associated fibroblasts as novel, targets in anti-cancer therapy? Lung Cancer 45 (Suppl. 2), S163-S175.
150. Fodde, R., Smits, R. and Clevers, H. (2001) APC, signal transduction and genetic instability in colorectal cancer. Nature Reviews. Cancer, 1 (1), 55-67.
151. Berlau, J., Glei, M. and Pool-Zobel, B.L. (2004) Colon cancer risk factors from nutrition. Analytical and Bioanalytical Chemistry, 378 (3), 737-743.
152. Potter, J.D. (1999) Colorectal cancer: molecules and populations. Journal of the National Cancer Institute, 91 (11), 916-932.
153. Gottesman, M.M., Fojo, T. and Bates, S.E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews. Cancer, 2 (1), 48-58.
154. Ohtsuki, S., Kamoi, M., Watanabe, Y., Suzuki, H., Hori, S. and Terasaki, T. (2007) Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biological & Pharmaceutical Bulletin, 30 (6), 1144-1146.
155. Ishida, S., Lee, J., Thiele, D.J. and Herskowitz, I. (2002) Uptake of the anticancer drug cisplatin mediated by the copper, transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America, 99 (22), 14298-14302.
156. Matherly, L.H., Hou, Z. and Deng, Y. (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Reviews, 26 (1), 111-128.
157. Zhang, J., Visser, F., King, K.M., Baldwin, S.A., Young, J.D. and Cass, C.E. (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Reviews, 26 (1), 85-110.
158. di Pietro, M., Sabates Bellver, J., Menigatti, M., Bannwart, F., Schnider, A., Russell, A., Truninger, K., Jiricny, J. and Marra, G. (2005) Defective DNA mismatch repair determines a characteristic transcriptional profile in proximal colon cancers. Gastroenterology, 129 (3), 1047-1059.
159. Huang, Y., Anderle, P., Bussey, K.J., Barbacioru, C., Shankavaram, U., Dai, Z., Reinhold, W.C., Papp, A., Weinstein, J.N. and Sadee, W. (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Research, 64 (12), 4294-4301.
160. Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., Andrews, D.T. et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nature Genetics, 24 (3), 236-244.
161. Chapman, J.M., Knoepp, S.M., Byeon, M.K., Henderson, K.W. and Schweinfest, C.W. (2002) The colon anion transporter, down-regulated in adenoma, induces growth suppression that is abrogated by E1A. Cancer Research, 62 (17), 5083-5088.
162. Li, H., Myeroff, L., Smiraglia, D., Romero, M.F., Pretlow, T.P., Kasturi, L., Lutterbaugh, J., Rerko, R.M., Casey, G., Issa, J.P. et al. (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proceedings of the National Academy of Sciences of the United States of America, 100 (14), 8412-8417.
163. Schweinfest, C.W., Spyropoulos, D.D., Henderson, K.W., Kim, J.H., Chapman, J.M., Barone, S., Worrell, R.T., Wang, Z. and Soleimani, M. (2006) slc26a3 (dra)-deficient mice display chloride-losing diarrhea, enhanced colonic proliferation, and distinct up-regulation of ion transporters in the colon. The Journal of Biological Chemistry, 281 (49), 37962-37971.
164. Ueno, M., Toyota, M., Akino, K., Suzuki, H., Kusano, M., Satoh, A., Mita, H., Sasaki, Y., Nojima, M., Yanagihara, K. et al. (2004) Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 25 (3), 134-140.
165. Zschocke, J., Allritz, C., Engele, J. and Rein, T. (2007) DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells. Glia, 55 (7), 663-674.
166. Schweinfest, C.W., Henderson, K.W., Suster, S., Kondoh, N. and Papas, T.S. (1993) Identification of a colon mucosa gene that is down-regulated in colon, adenomas and adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 90 (9), 4166-4170.
167. Kiemer, A.K., Takeuchi, K. and Quinlan, M.P. (2001) Identification of genes involved in epithelial-mesenchymal transition and tumor progression. Oncogene, 20 (46), 6679-6688.
168. Yamashita, S., Miyagi, C., Fukada, T., Kagara, N., Che, Y.S. and Hirano, T. (2004) Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature, 429 (6989), 298-302.
169. Gallagher, S.M., Castorino, J.J., Wang, D. and Philp, N.J. (2007) Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Research, 67 (9), 4182-4189.
170. Ho, E.A. and Piquette-Miller, M. (2006) Regulation of multidrug resistance by pro-inflammatory cytokines. Current Cancer Drug Targets, 6 (4), 295-311.
171. Shimakura, J., Terada, T., Shimada, Y., Katsura, T. and Inui, K. (2006) The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochemical Pharmacology, 71 (11), 1581-1588.
172. Nduati, V., Yan, Y., Dalmasso, G., Driss, A., Sitaraman, S. and Merlin, D. (2007) Leptin transcriptionally enhances peptide transporter (hPepT1) expression and activity via the cAMP-response elementbinding protein and Cdx2 transcription factors. The Journal ofBiological Chemistry, 282 (2), 1359-1373.
173. Guo, R.J., Suh, E.R. and Lynch, J.P. (2004) The role of Cdx proteins in intestinal development and cancer. Cancer Biology & Therapy, 3 (7), 593-601.
174. Suh, E. and Traber, P.G. (1996) An intestine-specific homeobox gene regulates proliferation and differentiation. Molecular and Cellular Biology, 16 (2), 619-625.
175. Witek, M.E., Nielsen, K., Walters, R., Hyslop, T., Palazzo, J., Schulz, S. and Waldman, S.A. (2005) The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clinical Cancer Research, 11 (24 Pt 1), 8549-8556.
176. Gross, I., Duluc, I., Benameur, T., Calon, A., Martin, E., Brabletz, T., Kedinger, M., Domon-Dell, C. and Freund, J.N. (2008) The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells. Oncogene, 27 (1), 107-115.
177. Ganapathy, M.E., Brandsch, M., Prasad, P.D., Ganapathy, V. and Leibach, F.H. (1995) Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT 2. The Journal of Biological Chemistry, 270 (43), 25672-25677.
178. Terada, T., Shimada, Y., Pan, X., Kishimoto, K., Sakurai, T., Doi, R., Onodera, H., Katsura, T., Imamura, M. and Inui, K. (2005) Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochemical Pharmacology, 70 (12), 1756-1763.
179. Mutoh, H., Satoh, K., Kita, H., Sakamoto, H., Hayakawa, H., Yamamoto, H., Isoda, N., Tamada, K., Ido, K. and Sugano, K. (2005) Cdx2 specifies the differentiation of morphological as well as functional absorptive enterocytes of the small intestine. The International Journal of Developmental Biology, 49 (7), 867-871.
180. Grotzinger, C., Kneifel, J., Patschan, D., Schnoy, N., Anagnostopoulos, I., Faiss, S., Tauber, R., Wiedenmann, B. and Gessner, R. (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut, 49 (1), 73-81.
181. Hinoi, T., Lucas, P.C., Kuick, R., Hanash, S. , Cho, K.R. and Fearon, E.R. (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology, 123 (5), 1565-1577.
182. Kwak, J.M., Min, B.W., Lee, J.H., Choi, J.S., Lee, S.I., Park, S.S., Kim, J., Um, J.W., Kim, S.H. and Moon, H.Y. (2007) The prognostic significance ofE-cadherin and liver intestine-cadherin expression in colorectal cancer. Diseases ofthe Colon and Rectum, 50 (11), 1873-1880.
183. Takamura, M., Ichida, T., Matsuda, Y., Kobayashi, M., Yamagiwa, S., Genda, T., Shioji, K., Hashimoto, S., Nomoto, M., Hatakeyama, K. et al. (2004) Reduced expression ofliver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Letters, 212 (2), 253-259.
184. Ko, S., Chu, K.M., Luk, J.M., Wong, B.W., Yuen, S.T., Leung, S.Y. and Wong, J. (2004) Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochemical and Biophysical Research Communications, 319 (2), 562-568.
185. Ko, S., Chu, K.M., Luk, J.M., Wong, B.W., Yuen, S.T., Leung, S.Y. and Wong, J. (2005) CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. The Journal ofPathology, 205 (5), 615-622.
186. Dean, M., Fojo, T. and Bates, S. (2005) Tumour stem cells and drug resistance. Nature Reviews. Cancer, 5 (4), 275-284.
187. Zhou, S., Schuetz, J.D., Bunting, K.D., Colapietro, A.M., Sampath, J., Morris, J.J., Lagutina, I., Grosveld, G.C., Osawa, M., Nakauchi, H. et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine, 7 (9), 1028-1034.
188. O'Brien, C.A., Pollett, A., Gallinger, S. and Dick, J.E. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445 (7123), 106-110.
189. Radeva, G., Buyse, M., Hindlet, P., Beaufils, B., Walker, F., Bado, A. and Farinotti, R. (2007) Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Digestive Diseases and Sciences, 52 (7), 1653-1661.
190. Monzani, E., Facchetti, F., Galmozzi, E., Corsini, E., Benetti, A., Cavazzin, C., Gritti, A., Piccinini, A., Porro, D., Santinami, M. et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. European Journal of Cancer, 43 (5), 935-946.
191. Florek, M., Haase, M., Marzesco, A.M., Freund, D., Ehninger, G., Huttner, W.B. and Corbeil, D. (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell and Tissue Research, 319 (1), 15-26.
192. Frank, N.Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A.M., Gasser, M., Sayegh, M.H., Sadee, W. and Frank, M.H. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Research, 65 (10), 4320-4333.
193. Buyse, M., Tsocas, A., Walker, F., Merlin, D. and Bado, A. (2002) PepT1-mediated fMLP transport induces intestinal inflammation in vivo. American Journal of Physiology - Cell Physiology, 283 (6), C1795-C1800
194. Merlin, D., Si-Tahar, M., Sitaraman, S.V., Eastburn, K., Williams, I., Liu, X., Hediger, M.A. and Madara, J.L. (2001) Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology, 120 (7), 1666-1679.
195. Ziegler, T.R., Fernandez-Estivariz, C., Gu, L.H., Bazargan, N., Umeakunne, K., Wallace, T.M., Diaz, E.E., Rosado, K.E., Pascal, R.R., Galloway, J.R. et al. (2002) Distribution of the H + /peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. The American Journal of Clinical Nutrition, 75 (5), 922-930.
196. Sundaram, U., Wisel, S. and Coon, S. (2005) Mechanism of inhibition of proton: dipeptide co-transport during chronic enteritis in the mammalian small intestine. Biochimica et Biophysica Acta, 1714 (2), 134-140.
197. Shi, B., Song, D., Xue, H., Li, J. and Li, N. (2006) Abnormal expression of the peptide transporter PepT1 in the colon of massive bowel resection rat: a potential route for colonic mucosa damage by transport of fMLP. Digestive Diseases and Sciences, 51 (11), 2087-2093.
198. Shi, B., Song, D., Xue, H., Li, N. and Li, J. (2006) PepT1 mediates colon damage by transporting fMLP in rats with bowel resection. The Journal of Surgical Research, 136 (1), 38-44.
199. Shu, H.J., Takeda, H., Shinzawa, H., Takahashi, T. and Kawata, S. (2002) Effect of lipopolysaccharide on peptide transporter 1 expression in rat small intestine and its attenuation by dexamethasone. Digestion, 65 (1), 21-29.
200. Vavricka, S.R., Musch, M.W., Fujiya, M., Kles, K., Chang, L., Eloranta, J.J., Kullak-Ublick, G.A., Drabik, K., Merlin, D. and Chang, E.B. (2006) Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine. Pflugers Archiv: European Journal ofPhysiology, 452 (1), 71-80.
201. Nielsen, C.U., Amstrup, J., Nielsen, R., Steffansen, B., Frokjaer, S. and Brodin, B. (2003) Epidermal growth factor and insulin short-term increase hPepT1-mediated glycylsarcosine uptake in Caco-2 cells. Acta Physiologica Scandinavica, 178 (2), 139-148.
202. Nielsen, C.U., Amstrup, J., Steffansen, B., Frokjaer, S. and Brodin, B. (2001) Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. American Journal ofPhysiology - Gastrointestinal and Liver Physiology, 281 (1), G191-G199.
203. Sitaraman, S., Liu, X., Charrier, L., Gu, L.H., Ziegler, T.R., Gewirtz, A. and Merlin, D. (2004) Colonicleptin: source of a novel proinflammatory cytokine involved in, IBD. The FASEB Journal, 18 (6), 696-698.
204. Dalmasso, G., Charrier-Hisamuddin, L., Thu Nguyen, H.T., Yan, Y., Sitaraman, S. and Merlin, D. (2008) PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134 (1), 166-178.
205. Landowski, C.P., Sun, D., Foster, D.R., Menon, S.S., Barnett, J.L., Welage, L.S., Ramachandran, C. and Amidon, G.L. (2003) Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. The Journal of Pharmacology and Experimental Therapeutics, 306 (2), 778-786.
206. Shin, H.C., Landowski, C.P., Sun, D. and Amidon, G.L. (1999) Transporters in the GI Tract, vol. 18, WILEY-VCH Verlag GmbH, Weinheim.
207. Baldwin, S.A., Beal, P.R., Yao, S.Y., King, A.E., Cass, C.E. and Young, J.D. (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Archiv: European Journal of Physiology, 447 (5), 735-743.
208. Palacin, M. (1994) A new family of proteins (rBAT and 4F2hc) involved in cationic and zwitterionic amino acid transport: a tale of two proteins in search of a transport function. The Journal of Experimental Biology, 196, 123-137.
209. Bisceglia, L., Purroy, J., Jimenez-Vidal, M., d'Adamo, A.P., Rousaud, F., Beccia, E. , Penza, R., Rizzoni, G., Gallucci, M., Palacin, M. et al. (2001) Cystinuria type I: identification of eight new mutations in SLC3A1. Kidney International, 59 (4), 1250-1256.
210. Botzenhart, E., Vester, U., Schmidt, C., Hesse, A., Halber, M., Wagner, C., Lang, F. , Hoyer, P., Zerres, K. and Eggermann, T. (2002) Cystinuria in children: distribution and frequencies of mutations inthe SLC3A1 and SLC7A9 genes. Kidney International, 62 (4), 1136-1142.
211. Gasparini, P., Calonge, M.J., Bisceglia, L., Purroy, J., Dianzani, I., Notarangelo, A., Rousaud, F., Gallucci, M., Testar, X., Ponzone, A. et al. (1995) Molecular genetics of cystinuria: identification of four new mutations and seven polymorphisms, and evidence for genetic heterogeneity. American Journal of Human Genetics, 57 (4), 781-788.
212. Durand, E., Boutin, P., Meyre, D., Charles, M.A., Clement, K., Dina, C. and Froguel, P. (2004) Polymorphisms in the amino acid transporter solute carrier family 6 (neurotransmitter transporter) member 14 gene contribute to polygenic obesity in French Caucasians. Diabetes, 53 (9), 2483-2486.
213. Brauers, E., Schmidt, C., Zerres, K. and Eggermann, T. (2006) Functional characterization of SLC7A9 polymorphisms assumed to influence the cystinuria phenotype. Clinical Nephrology, 65 (4), 262-266.
214. Schmidt, C., Tomiuk, J., Botzenhart, E., Vester, U., Halber, M., Hesse, A., Wagner, C., Lahme, S., Lang, F., Zerres, K. et al. (2003) Genetic variations of the SLC7A9 gene: allele distribution of 13 polymorphic sites in German cystinuria patients and controls. Clinical Nephrology, 59 (5), 353-359.
215. Deng, X., Shibata, H., Takeuchi, N., Rachi, S., Sakai, M., Ninomiya, H., Iwata, N., Ozaki, N. and Fukumaki, Y. (2007) Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. American Journal of Medical Genetics B. Neuropsychiatric Genetics, 144 (3), 271-278.
216. Dickel, D.E., Veenstra-VanderWeele, J., Cox, N.J., Wu, X., Fischer, D.J., Van Etten-Lee, M., Himle, J.A., Leventhal, B.L., Cook, E.H., Jr. and Hanna, G.L. (2006) Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Archives of General Psychiatry, 63 (7), 778-785.
217. Avissar, N.E., Ryan, C.K., Ganapathy, V. and Sax, H.C. (2001) Na( + )-dependent neutral amino acid transporter ATB(0) is a rabbit epithelial cell brush-border protein. American Journal of Physiology - Cell Physiology, 281 (3), C963-C971.
218. Larriba, S., Sumoy, L., Ramos, M.D., Gimenez, J., Estivill, X., Casals, T. and Nunes, V. (2001) ATB(0)/SLC1A5 gene. Fine localisation and exclusion of association with the intestinal phenotype of cystic fibrosis. European Journal of Human Genetics, 9 (11), 860-866.
219. Martin, M.G., Turk, E., Lostao, M.P., Kerner, C. and Wright, E.M. (1996) Defects in Na + /glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nature Genetics, 12 (2), 216-220.
220. Urban, T.J., Brown, C., Castro, R.A., Shah, N., Mercer, R., Huang, Y., Brett, C.M., Burchard, E.G. and Giacomini, K.M. (2008) Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clinical Pharmacology and Therapeutics, 83 (3), 416-421.
221. Urban, T.J., Yang, C., Lagpacan, L.L., Brown, C., Castro, R.A., Taylor, T.R., Huang, C.C., Stryke, D., Johns, S.J., Kawamoto, M. et al. (2007) Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenetics and Genomics, 17 (9), 773-782.
222. Wang, Y., Ye, J., Ganapathy, V. and Longo, N. (1999) Mutations in the organic cation/carnitine transporter OCTN2 in, primary carnitine deficiency. Proceedings ofthe National Academy ofSciences ofthe United States of America, 96 (5), 2356-2360.
223. Kivisto, K.T. and Niemi, M. (2007) Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceutical Research, 24 (2), 239-247.
224. Nguyen, T.T., Dyer, D.L., Dunning, D.D., Rubin, S.A., Grant, K.E. and Said, H.M. (1997) Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. Gastroenterology, 112 (3), 783-791.
225. Lu, Y., Kham, S.K., Foo, T.C., Hany, A., Quah, T.C. and Yeoh, A.E. (2007) Genotyping of eight polymorphic genes encoding drug-metabolizing enzymes and transporters using a customized oligonucleotide array. Analytical Biochemistry, 360 (1), 105-113.
226. Wang, W., Xue, S., Ingles, S.A., Chen, Q., Diep, A.T., Frankl, H.D., Stolz, A. and Haile, R.W. (2001) An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiology, Biomarkers & Prevention, 10 (9), 931-936.